Aveanna Healthcare (AVAH) reported $647.92 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 15.9%. EPS of $0.18 for the same period compares to $0.10 a year ago.
The reported revenue represents a surprise of +5.11% over the Zacks Consensus Estimate of $616.44 million. With the consensus EPS estimate being $0.13, the EPS surprise was +35.85%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Aveanna performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Hours - PDS: 12,056.00 hrs versus 11,748.27 hrs estimated by two analysts on average. Revenue rate - MS: $490.90 compared to the $490.58 average estimate based on two analysts. Unique patients served (UPS) - MS: 93 versus 92 estimated by two analysts on average. Revenue rate - PDS: $44.43 versus $43.56 estimated by two analysts on average. Revenue- PDS: $535.65 million versus the two-analyst average estimate of $511.81 million. The reported number represents a year-over-year change of +16.5%. Revenue- MS: $45.65 million compared to the $44.82 million average estimate based on two analysts. The reported number represents a change of +7.4% year over year. Revenue- HHH: $66.61 million versus the two-analyst average estimate of $61.57 million. The reported number represents a year-over-year change of +17.4%.View all Key Company Metrics for Aveanna here>>>
Shares of Aveanna have returned +0.7% over the past month versus the Zacks S&P 500 composite's +8.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Aveanna Healthcare Holdings Inc. (AVAH): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).